Large-scale testing (Phase 3)Not Yet RecruitingNCT07520318
What this trial is testing
This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Who this might be right for
Adults With Neovascular Age-related Macular Degeneration
Shenzhen Oculgen Biomedical Technology Co., Ltd. 255